Heron Therapeutics, Inc. (HRTX)Healthcare | Biotechnology | Cary, United States | NasdaqCM
0.38 USD
-0.01
(-2.305%) ⇩
(Oct. 14, 2026, 10:05 a.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 7:57 a.m. EDT
The long-term outlook is severely compromised by a catastrophic multi-year decline; the stock has lost over 92% of its value since 2016, with seven of the last nine years showing negative returns. Despite a recent 32% surge in acute-care revenue following a patent settlement, the market has priced in significant structural deterioration, evidenced by the relentless drop in share price and a negative forward P/E. The balance sheet is fragile, with debt significantly exceeding cash reserves, creating a precarious runway for a company that cannot yet generate profit. While the recent legal victory offers a glimmer of hope for top-line growth, the sheer magnitude of the historical decline and the lack of profitability suggest the business is currently in a survival mode rather than a growth phase. On the short end, the heavy put option flow confirms that traders are positioning for further weakness, making this a high-risk speculative vehicle rather than a viable investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.104619 |
| MSTL | 0.314206 |
| AutoARIMA | 0.316068 |
| AutoETS | 0.316068 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 0.07 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.417 |
| Excess Kurtosis | -0.94 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2147.568 |
| Revenue per Share | 0.818 |
| Market Cap | 72,447,640 |
| Forward P/E | -3.47 |
| Beta | 1.63 |
| Profit Margins | -22.52% |
| Website | https://www.herontx.com |
As of Oct. 10, 2026, 7:57 a.m. EDT: Speculators are overwhelmingly bearish, with massive open interest in deep out-of-the-money puts (strikes $2.00 and $3.00) relative to negligible call volume. This indicates a strong expectation of further downside or a 'naked put' hedge strategy against potential biotech litigation risks, while call activity is virtually non-existent.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.71111107 |
| Address1 | 25 Fenton Main Street |
| Address2 | Suite 300 |
| All Time High | 1,290.0 |
| All Time Low | 0.26 |
| Ask | 0.4066 |
| Ask Size | 4 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 2,785,020 |
| Average Daily Volume3 Month | 2,509,718 |
| Average Volume | 2,509,718 |
| Average Volume10Days | 2,785,020 |
| Beta | 1.625 |
| Bid | 0.3388 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | 0.031 |
| City | Cary |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.3816 |
| Current Ratio | 2.494 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.3909 |
| Day Low | 0.37 |
| Debt To Equity | 2,147.568 |
| Display Name | Heron Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,365,000 |
| Earnings Call Timestamp Start | 1,786,365,000 |
| Earnings Timestamp | 1,786,365,000 |
| Earnings Timestamp End | 1,793,709,000 |
| Earnings Timestamp Start | 1,793,709,000 |
| Ebitda | -8,731,000 |
| Ebitda Margins | -0.05775 |
| Enterprise To Ebitda | -20.719 |
| Enterprise To Revenue | 1.197 |
| Enterprise Value | 180,896,304 |
| Eps Current Year | -0.13 |
| Eps Forward | -0.11 |
| Eps Trailing Twelve Months | -0.18 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.3416 |
| Fifty Day Average Change | 0.03999999 |
| Fifty Day Average Change Percent | 0.11709599 |
| Fifty Two Week Change Percent | -71.11111 |
| Fifty Two Week High | 1.58 |
| Fifty Two Week High Change | -1.1984 |
| Fifty Two Week High Change Percent | -0.758481 |
| Fifty Two Week Low | 0.26 |
| Fifty Two Week Low Change | 0.1216 |
| Fifty Two Week Low Change Percent | 0.46769235 |
| Fifty Two Week Range | 0.26 - 1.58 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 556,983,000,000 |
| Float Shares | 146,524,213 |
| Forward Eps | -0.11 |
| Forward P E | -3.469091 |
| Free Cashflow | -8,837,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 128 |
| Fullday Change | -0.009000003 |
| Fullday Change Percent | -2.3047383 |
| Fullday Price | 0.3816 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.61935 |
| Gross Profits | 93,632,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00983 |
| Held Percent Institutions | 0.70252 |
| Implied Shares Outstanding | 189,852,307 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://phx.corporate-ir.net/phoenix.zhtml?c=115565&p=irol-irhome |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,389,571,200 |
| Last Split Factor | 1:20 |
| Long Business Summary | Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina. |
| Long Name | Heron Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 72,447,640 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_24366 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -34,049,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 55,266,006 |
| Number Of Analyst Opinions | 3 |
| Open | 0.3809 |
| Operating Cashflow | -11,606,000 |
| Operating Margins | -0.05427 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Phone | 858 251 4400 |
| Previous Close | 0.3906 |
| Price Eps Current Year | -2.9353848 |
| Price Hint | 4 |
| Price To Book | 12.309677 |
| Price To Sales Trailing12 Months | 0.47922078 |
| Profit Margins | -0.22522 |
| Quick Ratio | 1.435 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.009000003 |
| Regular Market Change Percent | -2.3047383 |
| Regular Market Day High | 0.3909 |
| Regular Market Day Low | 0.37 |
| Regular Market Day Range | 0.37 - 0.3909 |
| Regular Market Open | 0.3809 |
| Regular Market Previous Close | 0.3906 |
| Regular Market Price | 0.3816 |
| Regular Market Time | 1,791,986,729 |
| Regular Market Volume | 274,254 |
| Return On Assets | -0.02804 |
| Revenue Growth | 0.013 |
| Revenue Per Share | 0.818 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 189,852,307 |
| Shares Percent Shares Out | 0.24239999 |
| Shares Short | 46,021,379 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 44,864,084 |
| Short Name | Heron Therapeutics, Inc. |
| Short Percent Of Float | 0.30879998 |
| Short Ratio | 21.32 |
| Source Interval | 15 |
| State | NC |
| Symbol | HRTX |
| Target High Price | 9.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 7.0 |
| Target Median Price | 7.0 |
| Total Cash | 42,664,000 |
| Total Cash Per Share | 0.225 |
| Total Debt | 148,354,000 |
| Total Revenue | 151,178,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.18 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.7665 |
| Two Hundred Day Average Change | -0.3849 |
| Two Hundred Day Average Change Percent | -0.5021526 |
| Type Disp | Equity |
| Volume | 274,254 |
| Website | https://www.herontx.com |
| Zip | 27,511 |